Natco Pharma Q1 profit falls 57 pc to Rs 206.5 cr

Natco Pharma has reported a significant decline in its first-quarter profit, which dropped by 57% to Rs 206.5 crore. This sharp fall is primarily attributed to a decrease in sales for its key cancer drug, lenalidomide. Consequently, the company's consolidated revenues have also fallen compared to the previous year. Investors should note that while the core business showed some growth and total expenses were reduced, the overall financial performance has been weighed down by the drop in this specific product line.

The drop in lenalidomide sales is a key factor for investors to monitor. This drug has been a major revenue driver for the company, and any sustained weakness in its demand could impact future earnings. Additionally, the reduction in expenses offers a small positive sign, suggesting the company is managing its costs better. Going forward, investors will need to watch if the company can stabilize its sales and whether the core business growth can offset the volatility in its key product.